» Articles » PMID: 37261566

Cost of Implementing an Evidence-Based Intervention to Support Safer Use of Antipsychotics in Youth

Overview
Publisher Springer
Specialty Public Health
Date 2023 Jun 1
PMID 37261566
Authors
Affiliations
Soon will be listed here.
Abstract

To estimate the cost of implementing a clinical program designed to support safer use of antipsychotics in children and adolescents (youth) age 3-17 years at the time of initiating an antipsychotic medication. We calculate the costs of implementing a psychiatric consultation and navigation program for youth prescribed antipsychotic medications across 4 health systems, which included an electronic health record (EHR) decision support tool, consultation with a child and adolescent psychiatrist, and up to 6 months of behavioral health care navigation, as well as telemental health for patients (n = 348). Cost data were collected for both start-up and ongoing intervention phases and are estimated over a 1-year period. Data sources included study records and time-in-motion reports, analyzed from a health system perspective. Costs included both labor and nonlabor costs (2019 US dollars). The average total start-up and ongoing costs per health system were $34,007 and $185,174, respectively. The average total cost per patient was $2,128. The highest average ongoing labor cost components were telemental health ($901 per patient), followed by child and adolescent psychiatrist consultation ($659), and the lowest cost component was primary care/behavioral health provider time to review/respond to the EHR decision support tool and case consultation ($24). For health systems considering programs to promote safer and targeted use of antipsychotics among youth, this study provides estimates of the full start-up and ongoing costs of an EHR decision support tool, psychiatric consultation service, and psychotherapeutic services for patients and families.Trial registration: Clinicaltrials.gov, NCT03448575.

References
1.
Akincigil A, Mackie T, Cook S, Hilt R, Crystal S . Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children. Health Serv Res. 2020; 55(4):596-603. PMC: 7375997. DOI: 10.1111/1475-6773.13297. View

2.
Barclay R, Penfold R, Sullivan D, Boydston L, Wignall J, Hilt R . Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services. Health Serv Res. 2017; 52(2):561-578. PMC: 5346490. DOI: 10.1111/1475-6773.12539. View

3.
Bowser D, Henry B, McCollister K . Cost analysis in implementation studies of evidence-based practices for mental health and substance use disorders: a systematic review. Implement Sci. 2021; 16(1):26. PMC: 7953634. DOI: 10.1186/s13012-021-01094-3. View

4.
Bushnell G, Crystal S, Olfson M . Trends in Antipsychotic Medication Use in Young Privately Insured Children. J Am Acad Child Adolesc Psychiatry. 2020; 60(7):877-886. PMC: 8055725. DOI: 10.1016/j.jaac.2020.09.023. View

5.
Constantine R, Bengtson M, Murphy T, McPherson M, Andel R, Jones M . Impact of the Florida Medicaid prior-authorization program on use of antipsychotics by children under age six. Psychiatr Serv. 2012; 63(12):1257-60. DOI: 10.1176/appi.ps.201100346. View